Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;6(2):125-31.
doi: 10.1016/j.jalz.2010.01.011.

Genetic variation at a single locus and age of onset for Alzheimer's disease

Affiliations

Genetic variation at a single locus and age of onset for Alzheimer's disease

Michael W Lutz et al. Alzheimers Dement. 2010 Mar.

Abstract

This perspective article provides an opportunity to explain a new genetic finding for late-onset Alzheimer's disease (LOAD). It is specifically written for physicians and scientists who are interested in LOAD, but it may be relevant to those interested in identifying susceptibility variants for other complex diseases. The significant finding discussed here is that a variable-length, deoxythymidine homopolymer (poly-T) within intron 6 of the TOMM40 gene is associated with the age of onset of LOAD [Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 2009 December 22;[Epublication ahead of print]. This result was obtained with a phylogenetic study of the genetic polymorphisms that reside within the linkage disequilibrium (LD) block that contains the TOMM40, APOE, and APOC1 genes from patients with LOAD and age-matched subjects without disease. Although the data will have diagnostic, prognostic, and therapeutic strategy implications, this perspective is meant to place the inheritance pattern for this "complex" human disease into context, and to highlight the potential utility of applying phylogenetic tools to the study of the genetics of complex diseases.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr. Roses is the President of three companies filed as S-Corporations in the state of North Carolina: Cabernet Pharmaceuticals, Inc is a pipeline pharmacogenetic consultation and project management company that has other pharmaceutical companies as clients; Shiraz Pharmaceuticals, Inc. is focused on the commercialization of diagnostics, including companion diagnostics, for universities, pharmaceutical companies, and biotechnology companies; Zinfandel Pharmaceuticals is the sponsor of OPAL [Opportunity to Prevent Alzheimer’s Disease] which is a combined clinical validation of a diagnostic and a pharmacogenetic-assisted delay of onset clinical trial.

These companies are independent of Duke University but any intellectual property generated by Dr. Roses or his team is intended to be treated as Deane Drug Discovery Institute property once there is an established commercial value.

Figures

Figure 1
Figure 1. Phylogenetic tree that resolved with strong bootstrap support and without prior consideration of APOE allele for a 10 Kb region in the TOMM40-APOE LD block
A and B refer to the two clades at the first branch point; the boxed regions identify haplogroups of the indicated APOE allele and poly-T length polymorphism at rs10524523. Note that APOE3-long “523” and APOE4 haplotypes separate into clade A.
Figure 2
Figure 2. Poly-T repeats linked to APOE3 and APOE4
These histograms show the frequency distributions of lengths of the deoxythymidine homopolymers (number of T residues) at rs10524523 in linkage with APOE3 (top panel) or APOE4 (bottom panel). The three different categories of length are significantly different from each other. This is the analysis from cohort 1 cases and controls representing 210 chromosomes.
Figure 3
Figure 3. Diagram of exons 6 (E6) to 10 (E10) of TOMM40
The vertical lines represent SNPs that distinguish clades A and B; purple boxes in intron 6 indicate the locations of two poly-T tracts. The histograms indicate the frequency distributions of poly-T lengths at two loci.
Figure 4
Figure 4. Average age of LOAD diagnosis for APOE3/4 heterozygous individuals
Long refers to APOE3-very long poly-T haplotype; Short refers to APOE3-short poly-T haplotype. All individuals carried one copy of the APOE4-long poly-T haplotype.
Figure 5
Figure 5. Age of onset curves for individuals with the indicated genotypes using the information available in 1993
From [1]. Today we propose that each of the age of onset curves is an average of sub-curves. There are two curves for APOE3/4 individuals due to the presence of either a short or a long 523 polymorphisms linked to APOE3. There are likely three curves for APOE3/3 individuals due to the possible combination of alleles at 523, i.e. short/short, short/very long, and very long/very long.
Figure 6
Figure 6. Proposed clinical trial design
This study is designed to simultaneously validate the genetic marker and to test the efficacy of a therapeutic that delays the onset of LOAD.

Similar articles

Cited by

References

    1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3. - PubMed
    1. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41:1088–93. - PMC - PubMed
    1. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable length polymorphism determines the age of late-onset Alzheimer’s disease. Pharmacogenomics J. 2009 - PMC - PubMed
    1. Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, Dolan SM, Fortier I, Garcia-Closas M, Gwinn M, Higgins JP, et al. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol. 2009;170:269–79. - PMC - PubMed
    1. Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L, Dowzell K, Cichon S, Hillmer AM, O’Donovan MC, et al. A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling. BMC Med Genomics. 2008;1:44. - PMC - PubMed

Publication types

MeSH terms

Substances